Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.
Read the full article.
Hemostasis Today has more posts you may find interesting.
-
Apr 6, 2026, 06:25Katherine Bridge: My First Time at The EHA ReCon
-
Apr 6, 2026, 06:11Priya Prasad: Family Donations Are Not as Safe as We Usually Think
-
Apr 6, 2026, 05:48Isaac Okello: Turning Point from Reliance on Foreign Exports to Self – Reliance Through Local Production of Medical Supplies
-
Apr 6, 2026, 05:34Lena Volland: Scientific Exchange in Bleeding Disorders at the WFH 2026 World Congress
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination